CLINICAL STUDIES OF TA-058

Abstract

TA-058, a new semisynthetic penicillin derivative, has a broad antibacterial spectrum against gram-positive and gram-negative bacteria and also a potent bactericidal activity. Clinical evaluation of the drug in 9 cases of surgical infections was studied (3 with postoperative wound infection, one with intraabdominal abscess, one with intractable abdominal wall fistula, 3 with perineal infection after Miles' op. and one with pneumonia).
1.0 g of TA-058 was administered twice a day for 5-21 days by intravenous injection or intravenous drip infusion.
The results of clinical response were good in 6 cases, fair in one case and poor in 2 cases, Clinical efficacy rate was 66.7%.
In bacteriological response, 2 strains of Peptococcus, each one of α-Streptococcus, E. coli, E. cloacae, Neisseriaceae sp. and P.morganii were eradicated. 2 strains of S. aureus, one of E.coli and P. mirabilis were decreased. One strain of S. aureus, S. marcescens and B.fragilis remained unchanged. Eradication rate was 50.0 %.
No Side effects nor adverse reactions on clinical laboratory findings attributable to the drug were observed.